Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · January 20, 2022

Paclitaxel and Carboplatin vs Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial
J. Clin. Oncol 2022 Jan 10;[EPub Ahead of Print], MA Powell, VL Filiaci, ML Hensley, HQ Huang, KN Moore, KS Tewari, LJ Copeland, AA Secord, DG Mutch, A Santin, DP Warshal, NM Spirtos, PA DiSilvestro, OB Ioffe, DS Miller

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading